argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 mrt 2016 - 08:06
Statutaire naam
argenx SE
Titel
argenx's Partner Bird Rock Bio Demonstrates Potential for Gerilimzumab, A Novel SIMPLE Antibody(TM) Against IL-6 to Treat Rheumatoid Arthritis
Bericht
Breda, the Netherlands / Ghent, Belgium - argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today reported that its partner Bird Rock Bio (formerly RuiYi), a company focused on the discovery and development of novel biologic therapies, has announced that gerilimzumab, a novel SIMPLE AntibodyTM neutralizing the IL-6 cytokine, has demonstrated safety and pharmacokinetics that support low, infrequent dosing and the potential for favorable pricing.
Datum laatste update: 01 september 2024